18 results
Primairy objective:To investigate whether the pharmacokinetics of sunitinib are influenced by circadian rhythm.Secondary objective:- to investigate whether daily variation in CYP3A4 activity exists in humans, based on midazolam and 4beta-…
To investigate if sunitinib has clinical significant activity in patients with metastatic/recurrent paraganglioma/pheochromocytoma.
To evaluate the probability that the progression free survival (PFS) in the first-line treatment with RAD001 is non-inferior to the first-line treatment with sunitinib for patients with metastatic renal cell carcinoma (primary objective).…
The main objective of this pilot study is to determine intratumoral concentrations of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…
To identify predictive factors for response to sunintib treatment in patients with HCC. By discovering changes in pathways involved in HCC carcinogenesis due to sunitinib treatment in tissue/biomarkers and to correlate these changes to FDG-PET scan…
To evaluate the safety and tolerability of escalating doses of oral sunitinib in combination with standard doses of intravenous ifosfamide in patients with solid malignancies.
To assess the therapeutic activity of SU11248 in patients with exptensive disease small cell lung cancer who are either chemonaive or have a sensitive relapse
The purpose of this clinical trial is to test whether treatment of patients with NSCLC with erlotinib plus sunitinib is better than treatment with erlotinib plus placebo. All patients enrolling in this study will receive treatment with erlotinib.
Primary: • To determine the safety and feasibility of PK guided dosing of sunitinib Secondary:• To determine the objective response rate (according RECIST 1.1)• To determine the time to tumor progression and progression free survival• To validate…
To select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.
To determine whether sunitinib rechallenge in patients with mRCC, who had benefit from prior treatment with sunitinib and who progressed on both sunitinib and second-line therapy (or a period of more than 3 months without treatment), can again…
Answering the following questions:1. Main question: Is remifentanil a usefull medication for PSA in the emergency department?2. What is the recovery time of the patient when using fentanyl / propofol / remifentanil (time between last gift PSA…
During the course of the study 2 randomisation questions will be adressed. Both questions concern patients in the high risk group.Randomisation question 1: Will the addition of Doxorubicin to the first 4 standard IVA chemotherapy courses lead to a…
A phase II trial whose main objective is to investigate the response rate of the primary tumor following pretreatment with sunitinib
Primary objectives:- To determine the maximum tolerated dose (MTD) of sunitinib when administered once a week or once every two weeks.- To assess the safety and tolerability of sunitinib in a once weekly or once every two weeks dose schedule- To…
The proposed study is designed to test the hypothesis that the combination of anticoagulants, in particular Dalteparin plus Sunitinib, can be safely administered in a phase I feasibility trial in patients with renal cell cancer in which Sunitinib…
The main objective of this pilot study is to determine PKI concentration in tumor tissue after approximately two weeks of treatment.